Mode 1 | Model 2 | |||||
---|---|---|---|---|---|---|
All | Male | Female | ||||
OR (95 % CI) | p-value | OR (95 % CI) | p-value | OR (95 % CI) | p-value | |
Medication within 2-year prior to index datea | ||||||
 ICS (cDDDs per quartier) | ||||||
  No use | 1 | - | 1 | - | 1 | - |
  Lower dose (≦18.8)b | 2.09 (1.52–2.88) | <.0001 | 2.18 (1.56–3.04) | <.0001 | 1.16 (0.35–3.85) | 0.812 |
  Higher dose (>18.8) | 1.88 (1.32–2.66) | <0.001 | 1.77 (1.22–2.57) | 0.003 | 2.96 (0.87–10.04) | 0.082 |
 OCS (Hydrocortisone equivalent/quarter) | ||||||
  No use | 1 | - | 1 | - | 1 | - |
  Lower dose (≦90.0 mg)b | 1.48 (1.20–1.83) | <0.001 | 1.46 (1.16–1.84) | 0.001 | 1.59 (0.88–2.87) | 0.124 |
  Higher dose (>90.0 mg) | 1.54 (1.22–1.93) | <0.001 | 1.55 (1.22–1.98) | <0.001 | 1.51 (0.75–3.04) | 0.253 |